LSN2463359

In today's world, LSN2463359 has become increasingly relevant in different areas of society. Whether in the technological, cultural, political or social sphere, LSN2463359 has become a topic of constant interest and debate. There are many studies and research that have been carried out to fully understand the impact that LSN2463359 has on people's daily lives. In this article, we will explore different aspects related to LSN2463359, analyzing its importance, its implications and the different perspectives that exist around this topic. Without a doubt, LSN2463359 is a topic that leaves no one indifferent and that deserves our attention and reflection.

LSN2463359
Names
IUPAC name
N-Propan-2-yl-5-(2-pyridin-4-ylethynyl)pyridine-2-carboxamide
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
EC Number
  • 802-759-0
  • InChI=1S/C16H15N3O/c1-12(2)19-16(20)15-6-5-14(11-18-15)4-3-13-7-9-17-10-8-13/h5-12H,1-2H3,(H,19,20)
    Key: STAFRSGTRKNXHF-UHFFFAOYSA-N
  • CC(C)NC(=O)C1=NC=C(C=C1)C#CC2=CC=NC=C2
Properties
C16H15N3O
Molar mass 265.316 g·mol−1
Hazards
GHS labelling:[1]
GHS07: Exclamation mark
Warning
H302, H315, H319, H335
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa).

LSN2463359 is a drug used in scientific research.

Mechanism of action

LSN2463359 is a positive allosteric modulator of the mGluR5,[2] which means it increases the activity of glutamate (an excitatory neurotransmitter) at this receptor.

Potential uses

A study has found that LSN2463359 and similar drugs can be used as a treatment to some aspects of cognitive deficits in schizophrenia.[3] Another study also mention that it could be used in the treatment of schizophrenia due to the potential interactions between NMDA receptors and mGluR5.[4]

References

  1. ^ "N-Isopropyl-5-(pyridin-4-ylethynyl)picolinamide". pubchem.ncbi.nlm.nih.gov.
  2. ^ Gilmour, Gary; Broad, Lisa M.; Wafford, Keith A.; Britton, Thomas; Colvin, Ellen M.; Fivush, Adam; Gastambide, Francois; Getman, Brian; Heinz, Beverly A.; McCarthy, Andrew P.; Prieto, Lourdes; Shanks, Elaine; Smith, Janice W.; Taboada, Lorena; Edgar, Dale M. (January 2013). "In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat". Neuropharmacology. 64: 224–239. doi:10.1016/j.neuropharm.2012.07.030. ISSN 1873-7064. PMID 22884720.
  3. ^ Gastambide, Francois; Cotel, Marie-Caroline; Gilmour, Gary; O'Neill, Michael J.; Robbins, Trevor W.; Tricklebank, Mark D. (March 2012). "Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator". Neuropsychopharmacology. 37 (4): 1057–1066. doi:10.1038/npp.2011.298. ISSN 1740-634X. PMC 3280638. PMID 22129780.
  4. ^ Gastambide, Francois; Gilmour, Gary; Robbins, Trevor W.; Tricklebank, Mark D. (January 2013). "The mGlu₅ positive allosteric modulator LSN2463359 differentially modulates motor, instrumental and cognitive effects of NMDA receptor antagonists in the rat". Neuropharmacology. 64: 240–247. doi:10.1016/j.neuropharm.2012.07.039. ISSN 1873-7064. PMID 22884612.